Half year review: How Aussie pharma fared through H1 09
The first six months of 2009 have brought continuing change for pharma. The global financial crisis, mergers, job losses and a government watching PBS reform - what does the next six months hold? » more
Pfizer buys CSL drug - Boosts pulmonary portfolio; ASMI defends paracetamol - No need to follow US; PPIs may rebound - New study points to dependence » full report
The Health Department has been forced to put on hold its 22% price cut on meloxicam planned for August 1 while it fights Boehringer in the Federal Court
» full report
The government may have given the National Prescribing Service more dollars in last month's Budget but it also wants more for its money, a comprehensive analysis by the Menzies Centre for Health Policy shows » full report
A five-year patent extension granted to Schering-Plough's contraceptive Nuvaring may have significant implications for other drug plus delivery device combinations » full report
Over 60% of GPs regard visits from pharmaceutical reps as a positive experience, and even more actually open direct mail, research from Cegedim Strategic Data reports » full report
People in Pharma
Pharma lawyer joins ARC council
The Minister for Innovation, Industry, Science and Research, Senator Kim Carr, has appointed Robyn Baker to the Australian Research Council (ARC) Advisory Council » full report
Your people moves
Nothing interests people in pharma more than what people in pharma are doing and where they're heading. Click here to spread your news » full report
US President Barack Obama has secured the cooperation of the US pharma industry in reforms costing up to $80 billion, a decision that will have global effects writes our correspondent from the recent BIO meeting in Atlanta Georgia
» full report
